On September 30, 2026, a new publication referencing TB-500 appeared in the journal Frontiers in Oral Health. The paper, titled "Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases," was indexed under PubMed ID 42876687.
The publication is described as a narrative review combined with three clinical case reports. It is listed in the hypothesis-generating category rather than as a controlled clinical trial. TB-500 is noted in the context of regenerative peptides discussed within this review and case series.
No specific findings, outcomes, or efficacy data from the publication have been provided alongside this announcement. The listing only confirms the title, journal, and publication date. TB-500 remains classified as an unapproved compound intended for research purposes only, with no approved medical use.
Readers interested in the broader context of TB-500 research, including its regulatory status and other related developments, can consult the compound overview for additional background.